Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin J Uttenthal

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
The Journal of Gene Medicine|May 22, 2012
Challenges in T cell receptor gene therapyBenjamin J Uttenthal, Ignatius Chua, Emma C Morris, et al.
The New England Journal of Medicine|June 8, 2012
Clinical problem-solving. The wolf at the doorBenjamin J Uttenthal, D Mark Layton, Timothy J Vyse, et al.
British Journal of Haematology|March 2, 2022
Incidence and outcomes of post-transplant lymphoproliferative disease after 5365 solid-organ transplants over a 20-year period at two UK transplant centresAnna Santarsieri, John F Rudge, Irum Amin, et al.
British Journal of Haematology|February 22, 2022
Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guidelineGeorge A Follows, Sally F Barrington, Kaljit S Bhuller, et al.
Ejhaem|December 5, 2022
Managing relapsed refractory lymphoma with palliative oral chemotherapy: A multicentre retrospective studySimon J Bulley, Anna Santarsieri, Isabel C Lentell, et al.
Annals of Hematology|February 28, 2021
Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trialJames Russell, Angela Collins, Alexis Fowler, et al.
The Lancet. Oncology|December 14, 2024
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational studyAnna Santarsieri, Emily Mitchell, My H Pham, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
The Journal of Gene Medicine|May 22, 2012
Challenges in T cell receptor gene therapyBenjamin J Uttenthal, Ignatius Chua, Emma C Morris, et al.
The New England Journal of Medicine|June 8, 2012
Clinical problem-solving. The wolf at the doorBenjamin J Uttenthal, D Mark Layton, Timothy J Vyse, et al.
British Journal of Haematology|March 2, 2022
Incidence and outcomes of post-transplant lymphoproliferative disease after 5365 solid-organ transplants over a 20-year period at two UK transplant centresAnna Santarsieri, John F Rudge, Irum Amin, et al.
British Journal of Haematology|February 22, 2022
Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guidelineGeorge A Follows, Sally F Barrington, Kaljit S Bhuller, et al.
Ejhaem|December 5, 2022
Managing relapsed refractory lymphoma with palliative oral chemotherapy: A multicentre retrospective studySimon J Bulley, Anna Santarsieri, Isabel C Lentell, et al.
Annals of Hematology|February 28, 2021
Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trialJames Russell, Angela Collins, Alexis Fowler, et al.
The Lancet. Oncology|December 14, 2024
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational studyAnna Santarsieri, Emily Mitchell, My H Pham, et al.
Pageof 1